NEW YORK, NY / ACCESSWIRE / July 24, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Heron Therapeutics, Inc. (NASDAQ: HRTX)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/heron-therapeutics-inc-loss-submission-form?prid=2578&wire=1
Lead Plaintiff Deadline: August 5, 2019
Class Period: October 31, 2018 to April 30, 2019
Allegations against HRTX include that: (i) Heron had failed to include adequate Chemistry, Manufacturing, and Controls (“CMC”) and non-clinical information in its NDA for HTX-011; (ii) the foregoing increased the likelihood that the FDA would not approve Heron’s NDA for HTX-011; and (iii) as a result, Heron’s public statements were materially false and misleading at all relevant times.
Pivotal Software, Inc. (NYSE: PVTL)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/pivotal-software-inc-loss-submission-form?prid=2578&wire=1
Lead Plaintiff Deadline: August 19, 2019
Class Period: investors who purchased common stock pursuant or traceable to the April 2018 initial public offering and/or Pivotal securities between April 24, 2018 and June 4, 2019.
Allegations against PVTL include that: (i) Pivotal was facing major problems with its sales execution and a complex technology landscape; (ii) the foregoing headwinds resulted in deferred sales, lengthening sales cycles, and diminished growth as its customers and the industry’s sentiment shifted away from Pivotal’s principal products because the Company’s products were outdated, inadequate, and incompatible with the industry-standard platform; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Omnicell, Inc. (NASDAQGS: OMCL)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/omnicell-inc-loss-submission-form?prid=2578&wire=1
Lead Plaintiff Deadline: September 16, 2019
Class Period: October 25, 2018 to July 11, 2019
Allegations against OMCL include that: (1) the Company recognized revenue for certain transactions before fulfilling its performance obligations; (2) the Company engaged in improper accounting practices to meet revenue targets; (3) the Company experienced weaker demand for new product lines than it had previously projected; (4) as a result, the Company would be required to write-off certain inventory; (5) the Company misclassified certain expenses as capitalized expenditures; and (6) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects and prospects were materially misleading and/or lacked a reasonable basis.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong